Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
J Neural Transm (Vienna) ; 129(1): 95-103, 2022 01.
Article in English | MEDLINE | ID: mdl-34966974

ABSTRACT

Bipolar disorder shares symptoms and pathological pathways with other neurodegenerative diseases, including frontotemporal dementia (FTD). Since TAR DNA-binding protein 43 (TDP-43) is a neuropathological marker of frontotemporal dementia and it is involved in synaptic transmission, we explored the role of TDP-43 as a molecular feature of bipolar disorder (BD). Homogenates were acquired from frozen hippocampus of postmortem brains of bipolar disorder subjects. TDP-43 levels were quantified using an ELISA-sandwich method and compared between the postmortem brains of bipolar disorder subjects and age-matched control group. We found higher levels of TDP-43 protein in the hippocampus of BD (n = 15) subjects, when compared to controls (n = 15). We did not find associations of TDP-43 with age at death, postmortem interval, or age of disease onset. Our results suggest that protein TDP-43 may be potentially implicated in behavioral abnormalities seen in BD. Further investigation is needed to validate these findings and to examine the role of this protein during the disease course and mood states.


Subject(s)
Bipolar Disorder , Frontotemporal Dementia , Bipolar Disorder/pathology , Brain/metabolism , DNA-Binding Proteins/metabolism , Frontotemporal Dementia/diagnosis , Hippocampus/pathology , Humans
2.
Int J Geriatr Psychiatry ; 33(1): 14-20, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28055136

ABSTRACT

OBJECTIVE: We examined brain volume and atrophy in individuals with major depressive disorder (MDD) without dementia that were referred to a large autopsy service. We also examined potential risk factors for brain atrophy, including demographics and clinical variables. METHODS: In this study, 1373 participants (787 male) aged 50 years or older who died from natural causes were included. Participants with no reliable informant, with cognitive impairment or dementia, with a medical history of severe chronic disease, or with prolonged agonal state were excluded. Presence of MDD at least once in their lifetime was defined according to the Structured Clinical Interview for DSM. Brain volume was measured immediately after removal from the skull. RESULTS: Mean age at death was 68.6 ± 11.6, and MDD was present in 185 (14%) individuals. Smaller brain volume was associated with older age (p < 0.001), lower education (years; p < 0.001), hypertension (p = 0.001), diabetes (p = 0.006), and female gender (p < 0.001). In the multivariate analysis adjusted for sociodemographics and cardiovascular risk factors, smaller brain volume was not associated with major depression (ß = -0.86, 95% CI = -26.50 to 24.77, p = 0.95). CONCLUSIONS: In this large autopsy study of older adults, MDD was not associated with smaller brain volumes. Regardless of the presence of MDD, in this sample of older adults without dementia, we found that smaller brain volumes were associated with risk factors for brain neurodegeneration such as older age, diabetes, hypertension, and lower education. Copyright © 2017 John Wiley & Sons, Ltd.


Subject(s)
Brain/pathology , Depressive Disorder, Major/pathology , Aged , Aging/pathology , Atrophy/pathology , Autopsy , Cross-Sectional Studies , Diabetes Mellitus/pathology , Educational Status , Female , Humans , Hypertension/pathology , Life Style , Male , Middle Aged , Multivariate Analysis , Organ Size , Risk Factors
3.
J Neural Transm (Vienna) ; 122(6): 741-6, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25261015

ABSTRACT

The aim of this study was to elucidate whether glutathione is involved in lithium's ability to decrease carbonylation and nitration produced by complex I inhibition, which is consistently found in BD. Neuroblastoma cells were treated with rotenone, a complex I inhibitor. Our results suggest that glutathione is essential for lithium's ability to ameliorate rotenone-induced protein carbonylation, but not nitration.


Subject(s)
Electron Transport Complex I/antagonists & inhibitors , Glutathione/metabolism , Lithium Compounds/pharmacology , Protein Carbonylation/drug effects , Tyrosine/analogs & derivatives , Cell Line, Tumor , Cell Survival/drug effects , Cell Survival/physiology , Humans , Immunohistochemistry , Neuroblastoma/metabolism , Rotenone/pharmacology , Tyrosine/metabolism , Uncoupling Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL